Low-molecular-weight heparin biosimilars: potential implications for clinical practice

Harshal Nandurkar, Beng Chong, H Salem, Alexander Gallus, Vito Ferro, Ross McKinnon

    Research output: Contribution to journalArticlepeer-review

    3 Citations (Scopus)


    A working group of clinicians and scientists was formed to review the clinical considerations for use of low-molecular-weight heparin (LMWH) biosimilars. LMWH are biological molecules of significant complexity; the full complexity of chemical structure is still to be elucidated. LMWH biosimilars are products that are biologically similar to their reference product and rely on clinical data from a reference product to establish safety and efficacy. The complex nature of LMWH molecules means that it is uncertain whether a LMWH biosimilar is chemically identical to its reference product; this introduces the possibility of differences in activity and immunogenicity. The challenge for regulators and clinicians is to evaluate the level of evidence required to demonstrate that a LMWH is sufficiently similar to the reference product. The consensus opinion of the working group is that prior to clinical use a LMWH biosimilar should have proven efficacy and safety, similar to the reference product with prospective studies, which should be confirmed with a proactive post-marketing pharmacovigilance programme.

    Original languageEnglish
    Pages (from-to)497-500
    Number of pages4
    JournalInternal Medicine Journal
    Issue number5
    Publication statusPublished - May 2014


    • Biosimilar
    • Enoxaparin
    • Heparin
    • Low-molecular-weight heparin (LMWH)
    • Venous thromboembolism (VTE)


    Dive into the research topics of 'Low-molecular-weight heparin biosimilars: potential implications for clinical practice'. Together they form a unique fingerprint.

    Cite this